Core Viewpoint - Fuhong Hanlin's stock rose nearly 6% following the FDA approval of two biosimilar products, BILDYOS and BILPREVDA, in collaboration with Organon, enhancing its market position in the U.S. biosimilar sector [1] Group 1: Company Developments - Fuhong Hanlin's stock price increased by 5.78%, reaching 81.45 HKD, with a trading volume of 48.73 million HKD [1] - The FDA approved BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp), which are biosimilars to PROLIA and XGEVA, respectively [1] - The approval covers all indications for the original products in the U.S. market [1] Group 2: Partnership and Market Impact - In 2022, Fuhong Hanlin entered into a licensing and supply agreement with Organon, granting Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1] - The approval of these products strengthens Organon's biosimilar portfolio in the U.S., which has been developed over eight years and spans five major therapeutic areas [1]

Core Points - The Hong Kong Stock Exchange (HKEX) reprimanded Fuhong Hanlin (02696.HK) and its former CEO Liu Shigao for failing to fulfill due diligence obligations regarding a significant investment management agreement from 2019, which involved $117 million (approximately 840 million RMB) of IPO proceeds being misallocated [2][4][5] - As of the end of 2024, Fuhong Hanlin has $66.36 million (approximately 47 million RMB) in unrecovered investment funds [3] - Liu Shigao has been mandated to undergo 26 hours of compliance training to continue serving as a director of a company listed on the HKEX [2][6] Investment Management Agreement - The investment management agreement, signed by the CFO on the first day of the IPO, allowed the investment of $117 million through a third party, which was not disclosed to the public until 2023 [4][6] - HKEX stated that the investment did not align with the intended use of IPO proceeds as outlined in Fuhong Hanlin's prospectus, which was primarily for clinical trials and operational expenses [5][6] - The funds were fully utilized by the third party to subscribe to bonds and purchase promissory notes from private entities, raising concerns about potential conflicts of interest [11][12] Recovery Efforts - Fuhong Hanlin has been attempting to recover the investment since 2020, but as of 2024, a significant portion remains unrecovered [3][9] - The company has taken legal action to recover the outstanding investment amount, which has been classified as accounts receivable in their financial statements [13][14] - The independent investigation revealed that the company’s personnel genuinely aimed to achieve capital preservation through low-risk investments during the idle period of IPO funds [12][13] Corporate Governance - Liu Shigao's lack of involvement in the agreement's establishment and failure to ensure compliance with listing rules led to the reprimand from HKEX [6][7] - Fuhong Hanlin has experienced a high turnover of CFOs, with four changes since its IPO in 2019, indicating potential instability in financial oversight [13] - The company has acknowledged the need for improved governance and compliance practices following the reprimand [2][6]

Core Viewpoint - The Hong Kong Stock Exchange has issued a disciplinary action against Shanghai Henlius Biotech, Inc. and its former CEO, Dr. Liu Shigao, for compliance failures related to the company's IPO in 2019 [2][4]. Group 1: Disciplinary Action - The Hong Kong Stock Exchange criticized Henlius and Dr. Liu for failing to adhere to compliance standards, mandating Dr. Liu to complete 26 hours of training on regulatory and listing rule compliance before being eligible for reappointment as a director [4]. - The disciplinary action stems from a management agreement signed by the former CFO on the company's IPO day, which involved a $117 million investment from IPO proceeds that did not align with the stated use of funds in the prospectus [4]. Group 2: Company Performance - Henlius reported a revenue of 2.82 billion yuan for the first half of the year, a 2.7% increase year-on-year, with a net profit of 390 million yuan [8]. - For 2024, the company achieved a revenue of 5.724 billion yuan, reflecting a 6.1% year-on-year growth, and a net profit of 821 million yuan, marking a 50.3% increase [9]. Group 3: Product Portfolio and Market Presence - Henlius has six products approved for sale, covering 25 indications, including major monoclonal antibodies, with four products approved in various overseas markets [9]. - The company has a robust pipeline with 50 molecules and 10 research platforms, encompassing a diverse range of drug formats [9]. Group 4: Corporate History and Relationships - Dr. Liu co-founded Henlius in partnership with Dr. Jiang Weidong after returning to China in 2008, and he maintained a close relationship with the company even after his departure [6]. - In June 2023, Henlius and Dr. Liu's new venture, HanchorBio, announced a collaboration that includes a $10 million upfront payment and potential milestone payments totaling $192 million [6]. Group 5: Privatization Attempt - In June 2024, Fosun Pharma announced plans to privatize Henlius at specific share prices, citing underperformance in stock price and trading volume since the IPO [10]. - However, the privatization attempt was declared unsuccessful in January 2023 [11].

Core Viewpoint - Henlius has received FDA approval for two biosimilar products, BILDYOS® and BILPREVDA®, which are biosimilars to PROLIA® and XGEVA®, respectively, covering all indications approved for the original products in the U.S. [1] Group 1 - The FDA approved BILDYOS® (60mg/mL) for five indications, including osteoporosis [3] - The FDA approved BILPREVDA® (120mg/1.7mL) for three indications, including bone-related events [3] - This marks Henlius's third product approved in the U.S. [3] Group 2 - The approval reflects Henlius's commitment to scientific excellence and product quality [1] - The collaboration with Organon aims to enhance the accessibility of high-quality biologics for U.S. patients [1]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 上海復宏漢霖生物技術股份有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02696 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Core Viewpoint - The approval of BILDYOS and BILPREVDA by the FDA marks a significant advancement in improving accessibility to critical bone care treatments for millions of Americans, particularly the aging population [1][2] Company Summary - Fuhong Hanlin has successfully developed and produced biosimilars BILDYOS and BILPREVDA, which have received FDA approval, demonstrating the company's commitment to scientific excellence and product quality [1] - The collaboration with Organon aims to expand the accessibility of high-quality biologics, providing patients with treatment options that are equivalent in efficacy and safety to the original drugs [1] Industry Summary - The approval of BILDYOS and BILPREVDA is based on a comprehensive review of data, including structural and functional analyses, pharmacokinetic data, and a clinical comparative study, showing high similarity in safety, purity, and efficacy to the original drugs PROLIA and XGEVA [2] - The approval enhances Organon's portfolio of biosimilars in the U.S., which has been developed over eight years and covers five major therapeutic areas [2]

Core Viewpoint - The approval of two products of Dazhu Single Antibody Injection by the FDA marks a significant milestone for the company, being the first domestically produced Dazhu Single Antibody to be approved overseas [2] Company Summary - The company, Fuhong Hanlin, has announced that its Dazhu Single Antibody Injection products (60mg/mL and 120mg/1.7mL) have received FDA approval for eight indications, including osteoporosis and bone-related events [2] - With this approval, the company now has three products approved in the United States [2]

Core Viewpoint - The approval of BILDYOS and BILPREVDA by the FDA marks a significant advancement in improving accessibility to critical bone care treatments for millions of Americans, particularly the aging population [1][2] Group 1: Product Approval - The FDA has approved two biosimilar products, BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp), which are biosimilars to PROLIA and XGEVA, covering all indications previously approved for the original products in the U.S. [1] - The approval is based on a comprehensive review of data, including structural and functional analyses, clinical pharmacokinetics, and a clinical comparative study demonstrating high similarity in safety, purity, and efficacy to the original drugs [2] Group 2: Strategic Partnerships - In 2022, the company entered into a licensing and supply agreement with Organon, granting Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [2] - The approval of these biosimilars enhances Organon's portfolio in the U.S., which has been developed over eight years and covers five major therapeutic areas [2] Group 3: Company Commitment - The approval signifies the company's commitment to scientific excellence and product quality, as stated by the CEO, highlighting the goal of providing affordable treatment options that are equivalent in efficacy and safety to the original drugs [1]

Core Viewpoint - The approval of BILDYOS and BILPREVDA by the FDA marks a significant advancement in improving accessibility to critical bone care treatments for millions of Americans, particularly the aging population [1][2] Company Summary - Fuhong Hanlin has successfully developed and produced biosimilars BILDYOS and BILPREVDA, which have received FDA approval, demonstrating the company's commitment to scientific excellence and product quality [1] - The partnership with Organon aims to expand the accessibility of high-quality biologics, providing patients with treatment options that are equivalent in efficacy and safety to the original drugs [1] Industry Summary - The approval of BILDYOS and BILPREVDA is based on a comprehensive review of data, including structural and functional analyses, pharmacokinetic data, and a clinical comparative study, showing high similarity in safety, purity, and efficacy to the original drugs PROLIA and XGEVA [2] - The approval enhances Organon's portfolio of biosimilars in the U.S., which has been developed over eight years and covers five major therapeutic areas [2]

Core Viewpoint - The first domestically developed Dazhu single antibody from China has successfully received approval from the US FDA for market entry, marking a significant milestone for the company and the industry [1] Company Summary - The company, Fuhong Hanlin, announced that its Dazhu single antibody injection products (60mg/mL and 120mg/1.7mL) have been approved by the US FDA for the treatment of osteoporosis and eight other indications [1] - This approval represents the first instance of a domestically produced Dazhu single antibody being approved for sale overseas [1] - Currently, Fuhong Hanlin has three products approved in the United States [1] Industry Summary - The approval of a Chinese-developed drug by the US FDA highlights the growing capabilities and competitiveness of the Chinese biopharmaceutical industry in the global market [1] - The successful entry of this product into the US market may pave the way for further international approvals of Chinese-developed drugs, enhancing the industry's reputation and potential for growth [1]